Heterodimeric nuclear receptors proteins, genes encoding same, and usage thereof
CA 2106382 A1 · Owner: University Louis Pasteur · Inventors: Chambon, Pierre; Leid, Mark; Kastner, Philippe
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is based in part on the novel observation that two different types of nuclear receptors retinoic acid, receptors (RAR) and thyroid receptors (TR) dimerize with an RX receptor (RXR) to form a heterodimer which is capable of binding to retinoic acid response elements (RARE) or thyroid receptor response elements (TRE) at physiological conditions. Based on this observation, the present invention provides novel heterodimeric proteins methods of identifying agents capable of binding the heterodimers of the present invention, methods of identifying DNA sequences capable of being bound by the heterodimers and methods to identify RA metabolic enzymes and proteins which are …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 25, 1993. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 25, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 25, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.